Comparison of the therapeutic effect of the Persian Medicine Protocol with the common treatment of chronic rhinosinusitis: a randomized clinical trial.
Journal: 2018/November - Electronic physician
ISSN: 2008-5842
Abstract:
UNASSIGNED
Chronic rhinosinusitis is one of the most common diseases affecting the quality of life of patients. Patients suffer from high costs in the diagnosis and treatment of the disease. Frequent recurrence and failure of therapeutic protocols are among the most important issues in the management of this disease. In view of this, the use of traditional and complementary therapies to promote the treatment of this disease has been increasingly taken into account.
UNASSIGNED
Comparison of the effectiveness of the Persian Medicine Protocol with the conventional therapy in the treatment of chronic rhinosinusitis.
UNASSIGNED
A randomized clinical trial was conducted at Imam Reza Hospital in Mashhad, Iran from July 2016 to March 2017. For patients with chronic rhinosinusitis symptoms, endoscopy of the sinuses was performed by an ENT specialist and in the case of negative endoscopy, paranasal sinus CT scan was requested. A total of 42 patients with chronic rhinosinusitis were randomly assigned to two groups. The first group (classical) received systemic and intranasal cortisone, and the second group (traditional) received a therapeutic Persian medicine protocol including intranasal lavender oil, and Liquorice Marjoram Tea (L. M. tea) for six weeks. The symptoms of the patients were evaluated using the SNOT-22 questionnaire at the beginning of the study and at the sixth week. If no improvement occurs, treatment continued for 12 weeks. Data were analyzed by SPSS version 16, using ANOVA, independent-samples and paired-samples t-test, Wilcoxon signed-rank test, and simple linear regression.
UNASSIGNED
In 20 patients in the traditional group, the decrease in SNOT score was observed as 56% after 6 weeks treatment (p=0.001), which is similar to the effect of the first group (classical). Although there was no statically significant difference between the two groups, in clinical terms, the difference in mean systemic symptoms such as confusion with 1.05 (p=0.5) and fatigue with 1.63 (p=0.01) had more improvement in the traditional group, and the difference in mean local symptoms such as nasal congestion with 2.37 (p=0.78) and runny nose with 1.95 (p=0.14) had a more decrease in the classical group.
UNASSIGNED
The results of this trial indicate the effectiveness of the Persian Medicine Protocol (including Lavender oil and L.M tea) in the treatment of chronic rhinosinusitis, especially on improving systemic symptoms. Nevertheless more clinical studies are necessary to support the acquired results.
UNASSIGNED
This trial was registered at the Iranian Center for Clinical Trials (ID: IRCT2015112425217N1).
UNASSIGNED
This research is part of a PhD thesis and is funded by the Vice-Chancellor for Research at Mashhad University of Medical Sciences, Grant No. 931673.
Relations:
Content
Citations
(1)
Drugs
(3)
Similar articles
Articles by the same authors
Discussion board
Electronic Physician. Jun/30/2018; 10(7): 7017-7027
Published online Jul/24/2018

Comparison of the therapeutic effect of the Persian Medicine Protocol with the common treatment of chronic rhinosinusitis: a randomized clinical trial

Abstract

Background

Chronic rhinosinusitis is one of the most common diseases affecting the quality of life of patients. Patients suffer from high costs in the diagnosis and treatment of the disease. Frequent recurrence and failure of therapeutic protocols are among the most important issues in the management of this disease. In view of this, the use of traditional and complementary therapies to promote the treatment of this disease has been increasingly taken into account.

Objective

Comparison of the effectiveness of the Persian Medicine Protocol with the conventional therapy in the treatment of chronic rhinosinusitis.

Methods

A randomized clinical trial was conducted at Imam Reza Hospital in Mashhad, Iran from July 2016 to March 2017. For patients with chronic rhinosinusitis symptoms, endoscopy of the sinuses was performed by an ENT specialist and in the case of negative endoscopy, paranasal sinus CT scan was requested. A total of 42 patients with chronic rhinosinusitis were randomly assigned to two groups. The first group (classical) received systemic and intranasal cortisone, and the second group (traditional) received a therapeutic Persian medicine protocol including intranasal lavender oil, and Liquorice Marjoram Tea (L. M. tea) for six weeks. The symptoms of the patients were evaluated using the SNOT-22 questionnaire at the beginning of the study and at the sixth week. If no improvement occurs, treatment continued for 12 weeks. Data were analyzed by SPSS version 16, using ANOVA, independent-samples and paired-samples t-test, Wilcoxon signed-rank test, and simple linear regression.

Results

In 20 patients in the traditional group, the decrease in SNOT score was observed as 56% after 6 weeks treatment (p=0.001), which is similar to the effect of the first group (classical). Although there was no statically significant difference between the two groups, in clinical terms, the difference in mean systemic symptoms such as confusion with 1.05 (p=0.5) and fatigue with 1.63 (p=0.01) had more improvement in the traditional group, and the difference in mean local symptoms such as nasal congestion with 2.37 (p=0.78) and runny nose with 1.95 (p=0.14) had a more decrease in the classical group.

Conclusion

The results of this trial indicate the effectiveness of the Persian Medicine Protocol (including Lavender oil and L.M tea) in the treatment of chronic rhinosinusitis, especially on improving systemic symptoms. Nevertheless more clinical studies are necessary to support the acquired results.

Trial registration

This trial was registered at the Iranian Center for Clinical Trials (ID: IRCT2015112425217N1).

Funding

This research is part of a PhD thesis and is funded by the Vice-Chancellor for Research at Mashhad University of Medical Sciences, Grant No. 931673.

1. Introduction

Chronic rhinosinusitis refers to inflammation of the nasal mucosa and sinuses (1) and has several complications (2). Symptoms and signs are divided into two major and minor categories. The disease has a relatively high prevalence (3) and according to some evidence, its incidence and prevalence is increasing (4). The prevalence of this disease worldwide is about 13.5%. (3). The prevalence of this disease is high in Iranian society, as in a meta-analysis study, the rate of sinusitis in Iran of about 53% (between 40% and 65% with a 95% confidence interval) has been reported (5). However, it seems that this prevalence is more among patients with background illnesses. For example, in an examination of asthmatic patients in Iran, the prevalence of sinusitis in adults was 48.3% (6), and in children aged 2 to 16 years old 73.2% (7) has been reported. Chronic rhinosinusitis affects the quality of life, and is comparable to chronic disabling diseases (8) and regarding the burden of the disease and its complications, it is considered as one of the 10 most debilitating diseases (9). Economically, sinusitis treatment is expensive (10), as some studies show that its treatment costs are approximately 1.5 times more than other similar diseases (11). Meanwhile, during the treatment of this disease, there are frequent outpatient visits, numerous diagnostic and therapeutic measures and a reduction in the productivity of the workplace (12). Treatment options for acute and chronic sinusitis are currently proposed, including the use of corticosteroids, antibiotics, antihistamines and, if necessary, surgical procedures for sinuses (13). However, due to the heterogeneous nature of chronic sinusitis, many of these treatments cannot root out its background cause (14). In addition, in a number of patients who have been treated repeatedly with antibiotics or sinus surgery, there is an increased risk of colonization of antibiotic-resistant pathogens and surgical complications (1). The incidence of chronic rhinosinusitis after endoscopic surgery has been reported to be 60%, with 47% of them requiring re-surgical operation (15). Due to the low level of treatment in this disease and frequent recurrence, the use of traditional and complementary medicine is common (16), with about one third of patients with chronic rhinosinusitis using plant compounds to fix their problem (17). According to previous studies in Iran, one of the most common causes for referring to traditional medicine clinics was sinusitis (18). However, in the reported evidence, the effectiveness of medicinal plants in the treatment of chronic sinusitis is limited (19), but several studies have been conducted in relationship with using various medicinal herbs, including: Rumex patientia (Garden patience), Ecballium elaterium (Squirting cucumber), Stachys schtschegleevii (Poulk), Pelargonium sidoides (African geranium) (2022). On the other hand, in the Persian medicine literature, a disease called “NAZLA” is mentioned whose symptoms and signs are compatible with chronic rhinosinusitis (23), and for which, various therapies have been mentioned (24). The main objective of this study was to determine the effectiveness of the Persian-based therapeutic protocol on chronic rhinosinusitis compared with classical drug therapy, and its specific objectives were the following: Determination of the effectiveness of the Persian Medicine Protocol in the treatment of chronic sinusitis based on the SNOT-22 test, determining the effectiveness of classical medicine in the treatment of chronic sinusitis according to the SNOT-22 test, and finally comparing the effectiveness of the Persian Medicine Protocol with conventional therapy for the treatment of chronic sinusitis, based on the SNOT-22 test. In this regard, the researchers have attempted to design and implement a clinical trial study of the effects of lavender, marjoram and licorice plants on chronic rhinosinusitis.

2. Material and Methods

2.1. Research design

This study was a randomized, single-blind clinical trial on patients with chronic rhinosinusitis from July 2016 to March 2017.

2.2. Population studied

The population under study was people with chronic rhinosinusitis and the statistical sample included individuals with chronic rhinosinusitis symptoms referring to the specialized centers of ENT and the Persian medicine of Imam Reza Hospital, a recessive center affiliated to Mashhad University of Medical Sciences (MUMS) in northeastern Iran. Patients with typical symptoms of chronic rhinosinusitis (based on the latest diagnostic criteria for chronic rhinosinusitis [AAO-HNS] in the United States of America in 2015) with the diagnosis of ENT, were examined by endoscopic sinuses or spinal paranasal sinus CT scans and entered the research plan if they had entry criteria (Figure 1).

2.3. Entry and exit criteria

The following cases were considered as inclusion criteria: aged 18 to 50 years, having at least two signs of symptoms: Mucosal septic secretion (anterior, posterior, or both), nasal obstruction (congestion), pain, pressure, decreased sense of smell, the presence of the above symptoms for at least 12 weeks, proven inflammation with at least one of the following ways: Observing mucosal septic secretions (non-transparent) or edema in the middle meatus or anterior region of ethmoid, the presence of polyps in the nasal cavity or middle meatus, or radiological imaging indicating inflammation in the paranasal sinuses. Exit criteria included chronic sinusitis with acute infection of respiratory microbial infections, chronic sinusitis associated with anatomical obstruction requiring surgery, sensitivity or contraindication to the components of the drug combination of traditional and Persian medicine in patients, pregnancy, immunodeficiency or history of hypertension.

2.4. Interventions

Patients who had inclusion criteria were randomly assigned to traditional and classical groups, and questionnaires of demographic and clinical information were completed. Each group was treated in parallel with one of two treatments in the following way: 1) Patients in the classical group (control group), inhaler corticosteroid (flixonase), received 2 puffs per day, plus daily nasal washings with normal saline serum at two times in the morning and at night. In cases of no recovery, systemic corticosteroid (as prednisone tablets at a dose of 1 mg/kg) that was tapered within 5 days was prescribed; 2) Patients in the traditional group (intervention group) received L.M tea as a combination of 5-gram packs containing 2 grams of Licorice root (Glycyrrhiza glabra) and 3 grams of Marjoram leaves (Origanum vulgare). The patient adds the contents of each package to 200 cc of boiling water which is steeped for 20 minutes and then filtered. Consumption, was three times an hour after food, in a lukewarm and sipping manner. In addition, an intranasal oily product was prepared for these patients. Patients in the intervention group dropped this oil locally up to 2–3 drops per nostril every night before bedtime. The method of preparation of this oil was 3 weeks maceration of lavender (Lavandula angustifolia) flower in pure olive oil. The method of oil extraction was based on the sources of Persian medicine. According to this instruction, to get the oil of the flowers, they should be put in oil and placed in an appropriate place (such as the sunlight), and once a week (for up to three weeks) they should be cleaned and refilled (25). For this purpose, 20 grams of lavender flowers were placed inside a beaker containing 300 cc of olive oil (Extra virgin type, Minodasht brand), so that about one third of the beaker contained only olive oil without lavender. After 10 days of initial immersion, all the lavender flowers of the above composition were separated from the oil first by metallic filter and then by sterilized gauze, and again, the same amount of lavender flower was added to the remaining oil, and then immersed. After 10 days from the second immersion, the plant mass was isolated by using sterile gauze and under pressure, and the obtained oil was poured into 15 centrifuge tubes and centrifuged for 20 minutes at 3000 rpm. Two grams of licorice and three grams of marjoram were packed in nylon bags and were ready to be delivered to the patients after labeling. The originality of the plants used in this study was confirmed by a botanical expert of the Plant Sciences Research Center of Ferdowsi University of Mashhad (Herbarium Numbers 14328 and 14261 belonging to marjoram and licorice, respectively).

2.5. Outcomes

Based on the Persian version of the SNOT-22 questionnaire whose validity and reliability was confirmed by Jalessi et al. (2013), (Cronbach’s Alpha coefficient = 0.898) (26), the change in the score of the questionnaire and each single symptom was considered as the primary outcome, and the symptom recovery time was also considered as the secondary outcome. The SNOT-22 questionnaire contains 22 questions. These questions relate to the prominent features of the nose and throat (such as nasal congestion, runny nose), localized non-nasal symptoms (such as pain and fullness of ear), symptoms associated with sleep quality (such as difficulty falling asleep) and general symptoms (such as fatigue and dizziness). Question scores vary based on six degrees (from 0 to 5). The SNOT-22 questionnaire was filled at the beginning of the study (week zero) and the end of the week 6 and evaluated for changing the severity of the symptoms. The treatment was stopped for patients who had clinical symptom relief and patients with all or part of the symptoms were treated for 12 weeks. Finally, the SNOT-22 questionnaire was completed for them. In case of possible complications, the patient was registered in the relevant form and in case of severe complication the patient was excluded from the study.

2.6. Sample size

With the help of the PASS software and based on the 90% confidence estimate for the difference between the mean scores of the SNOT-22 questionnaire, with an error estimation of 8 scores and a standard deviation of 15 for both groups, the sample size was considered to be 20 in each group with a 10% drop in each group, 22 samples were selected.

2.7. Allocation, blinding and randomization

Patients who had the criteria for entering the study were randomly assigned to traditional and classical groups and demographic information questionnaires were filled out with clinical information. Each group was treated with one of two treatments in parallel. Due to the difference in the type of drug interventions and how it was used in two groups that were differentiated by patients, blindness was not possible in this regard. But each patient was unaware of the treatment received by other participants in the study, and the analyst was not aware of the results of the patients. Therefore, this study was done randomly and single blind.

2.8. Statistical analysis

Data were entered into the computer after evaluation and analyzed by SPSS software version 16. At first, the characteristics of each group based on descriptive statistical methods including central indices, distribution and frequency distribution were studied and described. Then, for quantitative variables, the normality of their distribution was first measured using the Kolmogorov-Smirnov test. Data were analyzed using independent and paired-samples t-test, repeated measures (ANOVA), Wilcoxon signed-rank test, and simple linear regression. In all calculations, α 0.05 was considered as the significant level.

2.9. Ethics of research

The present study has been approved by the Ethics Committee for Research at Mashhad University of Medical Sciences (Ref: 931673, dated November 07, 2015). Patients were informed about this study and signed the consent form individually. Participation was completely voluntary and participants were allowed to leave at any time. In order to ensure that no financial, mental or physical harm occurred to the participants, an accessible telephone number was provided to contact at any time if information on the research or medical assistance was required. All participants’ data were received and kept confidential.

3. Results

3.1. Entry, screening and completing intervention

During the period from July 2016 to March 2017, 86 patients with symptoms of chronic rhinosinusitis referred to the specialized otorhinolaryngology and Persian medicine clinics of Imam Reza Hospital in Mashhad. Of these patients, after examination by an ENT, and performing endoscopic sinuses or CT scan of paranasal sinuses, 42 patients who were diagnosed with chronic rhinosinusitis were eligible to enter the trial. During the clinical trial, 2 patients in the group were treated with traditional medicine due to complications (one due to hypertension and another for the exacerbation of symptoms) failed to complete the treatment process, and 1 patient from the classical medicine department (due to the lack of recovery of symptoms leading to surgery) failed to complete the treatment.

3.2. Demographic findings

The mean age of participants in the study was 38.86 years with a standard deviation of 10.35. Of the patients studied, 64.3% were male and 35.7% were female. A total of 59.5% of the participants in the study had university education and the rest had lower qualifications. Furthermore, 76.2% of the patients in the project were employed (Table 1).

3.3. Intervention findings

In paraclinical examination, 82% of patients had endoscopic evidence of chronic rhinosinusitis. Also, in 81% of patients, chronic rhinosinusitis was found in paranasal sinus CT scans. Among the criteria for diagnosis of chronic rhinosinusitis, based on the American Academy of Otorhinolaryngology and the American Academy of Neck Surgery (AAO-HNS), all patients had nasal congestion or nasal-anterior or posterior secretion (100% of cases), however, pain or pressure in the face, and reduced or absent olfaction were reported from 78.6% and 85.7% of patients, respectively. Kolmogorov Smirnov test was used to check the normality of the quantitative variables used in the study. The results finally showed that all the variables used in the study had normal distribution. In examining the SNOT scores in the two traditional and classical groups whose results are presented in Table 2, SNOT scores were not significantly different in the two groups in the three stages of follow-up, but in analyzing the effect of intervention by group analysis, variance analysis showed that the scores were significantly different during the three stages. On the other hand, as shown in Table 3, comparison of SNOT scores in the third monitoring (the 12th week treatment) with the second monitoring (6th weeks treatment) indicates a decrease in the SNOT score in the traditional group and increase in the classical group. The evaluation of classified SNOT scores in both groups before and after intervention, as shown in Table 3, indicates that SNOT scores vary in both groups before and after intervention and the severity of symptoms in both groups decreased after intervention, especially as the percentage of “very severe” stage was much less than “very mild” stage, and this decrease in intensity from stage 3 is very tangible. Table 4 compares the single marker of patients’ symptoms before and after intervention in comparing the two treatment groups.

4. Discussion

The results of this trial showed that the treatment protocol based on Persian medicine, including the lavender oil, along with L.M tea, could be effective in treating patients with chronic rhinosinusitis and its effects on reducing or eliminating the 22-digit symptoms in the SNOT22 questionnaire are similar to the therapeutic effect of the current protocol of classic medicine. Comparing the scores of SNOT items between the traditional and classical groups also showed three categories of results: Accordingly, the symptoms of the first category (which didn’t show statistical or clinical difference between two groups) were sneezing, coughing, ear pain, fatigue after sleep, disappointment, restlessness, and irritability. In the second category of symptoms, there were fatigue and sadness, which both were clinically and statistically lower in the traditional group than the classical, and this difference was statistically significant. In the case of “sadness”, there was a significant improvement in the severity of symptoms in the traditional group compared with classical, while the difference was statistically significant. Of course, in the case of the sign “blowing the nose”, this difference was significant in favor of classical treatment. In addition to the above symptoms, 13 other symptoms are classified in the third category, showing a notable difference in the severity of post-treatment symptom between the traditional and classical groups, but this difference is not statistically significant. Accordingly, all of the local symptoms of the nasal cavity (including nasal secretion, nasal congestion, decreased olfactory sensation and post nasal discharge), with the exception of reduced thickness of nasal secretions, which responded better to classical treatment, although it was not statistically significant. But systemic symptoms of patients, with the exception of the difficulty of falling asleep (including confusion, waking up and not having a good night’s sleep, decreased efficacy, decreased focusing and embarrassment), better responded to traditional treatment and, despite not being statistically significant, compared to the classical treatment group, were more decreased.

Regarding the higher clinical improvement of systemic symptoms in response to traditional treatment, it can be preferable in some instances. For example, in a patient with the prolonged period of rhinosinusitis and recurrence after treatment with classical treatments, the use of a full 12-week course of treatment with the traditional protocol may be more appropriate; while, in a patient who recently had chronic rhinosinusitis or no resistance and has no long-term desire for treatment, any of the protocols in classical medicine or traditional medicine, depending on the patient’s preference, can be selected. Few studies have been done about the effects of the plants used in the present clinical trial (i.e. licorice, marjoram, lavender and olive oil). Madani et al. studied the effect of marjoram on 32 patients (compared with 32 controls) in a randomized, double-blind clinical trial (27). Based on this study, all symptoms of the patients, including headache, nasal congestion, sinus pain, throat secretions, etc. (except reduction of sense of smell and nasal secretion) were found to be remarkably decreased (27), which is similar to the effects observed in our research. In a study by Neher et al., several oily extracts were tested on the ciliary movement of nasal mucosa, and concluded that some herbal remedies, including lavender oil, could increase the ciliary beat frequency (CBF), which its impairment leads to chronic rhinosinusitis (28). The antimicrobial, anti-inflammatory, augmentative, and mucosal effects that can be effective in the treatment of chronic rhinosinusitis are reported in each of the above plants (whose major active ingredients are listed in Table 5). In a study by Giovannini et al. on the effect of Lavandula angustifolia essential oil on macrophage reaction from Staphylococcus aureus infection, this essential oil increased phagocytosis speed and increased the defense of intracellular antibacterial activity by macrophages (29). Another study by Ozogul on a number of herbal essential oils affecting food-borne pathogens showed that lavender essential oil can be effective as an antimicrobial against these pathogens (30). Prusinowska et al. also reported antimicrobial and antioxidant properties in lavender (31). These antimicrobial effects may confirm the findings of the present study on the local use of lavender oil in the pathophysiology of microbial contamination. In another study, conducted by Georgiev et al. on the lavender immune effects, lavender flowers contain polysaccharides that are immune-augmenter and can protect immune deficiencies (32). In a similar study, Gostner et al. concluded in a laboratory study that the effects of lavender on the immune system and neuroendocrine were due to its effect on tryptophan metabolism (33). Of course, in studies of short-term exposure to lavender through inhalation of oil, no significant changes were observed in immunological parameters (such as interleukins 6 and 10) (34, 35). In the case of olive oil, although some studies indicate its anti-inflammatory effects in topical use (36), most studies have shown antimicrobial effects (37), immunosuppressive (38, 39) and antioxidant (4043) effects on systemic use.

The study of the use of marjoram in the treatment of sinusitis, with the exception of the study by Madani et al., did not show any results. However, antibacterial effects (4446), antifungal (47, 48), and antioxidant (49) of this plant have been evaluated and shown to be positive. Licorice also has showed anti-viral (50), antibacterial (51), antifungal (52), anti-oxidant (53), anti-inflammatory (54, 55) and immune enhancer (56) effects in various research but based on the studied articles, it hasn’t been used directly in the treatment of chronic sinusitis. In addition to the above mentioned findings about the effectiveness of the plants used in the current trial, teachings in Persian Medicine Literature also reveals significant effects in justifying its usage for rhinosinusitis. Among the writings of Bu-Ali Sina in the Book of Law, he attributes the effects of breakdown of waste materials and the opening of obstruction to marjoram (57), and Hakim Jorjani regards it as a treatment for nasal congestion (58). Among the effects of licorice in these books is the excretion of thick mucus (59). The therapeutic effects of lavender on NAZLA have been mentioned in Persian medicine books (60) and its use has been shown to enhance brain functions and improve mental status (61). Considering the above points, it might be possible to justify the better result of Persian protocol in reducing systemic symptoms of patients, and in patients with prolonged recurrence, reduced mental and emotional functioning, and reduced social and occupational activity due to chronic rhinosinusitis, this therapy package is preferred.

5. Limitations

The main limitation of the present study was the lack of ease of use of an oral remedy in Persian medicine compared to common forms. From the phytochemical point of view, due to the use of four different herbs, it is not possible to attribute the effects of the research to a particular active ingredient or at least a certain plant.

6. Conclusions

In summary, the present study showed that a therapeutic package based on Persian medicine can be effective in the treatment of chronic rhinosinusitis, and in addition, it would promote systemic symptoms, especially the symptoms of subjective emotional and social efficacy, more than classical treatment.

Figure 1
Flowchart of the clinical trial based on CONSORT
Table 1
Demographic information of the participants
Variablen%
SexMale2764.3
Female1535.7
EducationIlliterate24.8
Primary School49.5
Secondary School614.3
High School511.9
University2559.5
EmploymentWorking3276.2
Workless1023.8
Marital statusYes3788.1
No511.9
SmokingYes37.3
No3892.7
Table 2
Mean and standard deviations of SNOT scores by groups
Follow up level based on SNOTTraditional group (Mean ± SD)Classic group (Mean ± SD)Results of Independent-samples t-test
SNOT 148.31±18.7848.29±14.7t= −0.002; p-value=0.998
SNOT 221.31±12.5722.57±9.29t= 0.147; p-value=0.884
SNOT 315.25±12.4628.71±20.68t= 1.94; p-value= 0.065
Result of the ANOVAF= 33.07; p-value<0.001F= 17.42; p-value<0.001-

SNOT 1: SNOT scores at the patient’s admission, SNOT 2: SNOT scores in the second checking (sixth week of treatment), SNOT 3: SNOT scores in the final checking (12th week of treatment)

Table 3
Frequency and percentage of groups before and after intervention
GroupSeverity of rhinosinusitis according to SNOT scorePercent before interventionPercent in the first follow upResult of Wilcoxon signed-rank test
Traditional1 (Very mild problem)1560Z= −3.12; p-value= 0.002
2 (Mild or slight problem)3530
3 (Moderate problem)405
4 (Severe problem)100
5 (Problem as bad as it can be)00
Classic1 (Very mild problem)9.168.2Z= −3.78; p-value<0.001
2 (Mild or slight problem)5027.3
3 (Moderate problem)36.44.5
4 (Severe problem)4.50
5 (Problem as bad as it can be)00
Table 4
Comparison of treatment response on the symptoms of patients before and after intervention in each group
SymptomMean before intervention (Mean ± SD)Mean after intervention (Mean ± SD)Mean difference
TraditionalClassicp-valueTraditionalClassicValueTraditionalClassic
Need to blow nose2.68±1.62.59±1.50.851.68±1.10.82±1.20.0211.77
Blockage/congestion of nose3.32±1.24.14±10.241.63±1.21.77±1.90.781.692.37
Sneezing1.58±1.31.32±1.60.580.47±0.60.45±10.941.110.87
Runny nose2.47±1.42.77±1.60.541.47±1.50.82±1.20.1411.95
Cough1.89±1.31.73±1.70.730.74±10.5±0.80.431.151.23
Post nasal discharge3.73±1.23.36±1.40.701.48±1.11.18±1.20.862.252.18
Thick nasal discharge3.16±1.52.77±1.60.441.21±0.910.91±10.342.951.86
Ear fullness1±1.51.32±1.60.480.58±10.14±0.30.070.421.18
Dizziness1.58±1.380.86±0.880.060.53±0.90.36±0.80.51.050.5
Ear pain0.63±0.80.46±0.80.500.14±0.30.990.630.32
Facial pain/pressure2.68±1.71.77±1.50.081.16±1.30.68±1.20.241.521.09
Sense of smell/taste2.84±1.73.86±1.50.052.32±2.12.18±1.90.830.521.68
Difficulty falling asleep1.21±1.72.23±1.90.910.26±0.70.86±1.20.070.951.37
Waking up at night1±1.52.36±20.020.37±0.80.68±1.10.330.631.68
Lack of a good night’s sleep1.89±1.72.23±1.90.570.26±0.90.41±0.90.621.631.82
Waking up tired2.11±1.82.09±1.90.980.89±10.82±10.811.221.27
Fatigue2.79±1.11.95±1.40.831.16±0.80.5±0.70.011.631.45
Reduced productivity2.47±1.51±1.20.0020.68±10.41±0.70.331.790.59
Reduced productivity2.63±1.51.14±1.30.0020.95±10.45±0.80.11.680.69
Frustrated/restless/irritable2.42±1.61.55±1.40.080.74±0.90.45±0.70.31.681.1
Sad2±1.50.68±1.10.0030.32±0.70.36±0.70.041.680.32
Embarrassed1.05±1.50.32±10.080.26±0.700.10.790.32
Table 5
Major active ingredients in plants used in the study
Medicinal plantActive ingredients
Lavandula angustifoliaLinalool, Linalyl acetate, Tannins, Hydroxcoumarins, Caffeic acid
Glycyrrhiza glabraTriterpene saponins, Flavonoids, Isoflavonoids, Hydroxycoumarins, Steroids
Origallum vulgareVolatile oil (carvacrol, gamma-terpinene, p-cymene), Flavonoids, Caffeic acid
Olea europaeaChief fatty acids (oleic acid, palmitic acid, linoleic acid), Steroids, Tocopherols

Footnotes

iThenticate screening: November 28, 2017, English editing: March 27, 2018, Quality control: March 28, 2018
This article has been reviewed/commented by five experts
Funding/research project approval: 931673 (Mashhad University of Medical Sciences)
Ethics approval: 931673, dated November 07, 2015 (Mashhad University of Medical Sciences)

Trial registration:

This trial has been registered with IRCT ID: IRIC IRCT2015112425217N1 at the Iranian Center for Clinical Trials.

Conflict of Interest:

There is no conflict of interest to be declared.

Authors’ contributions:

All authors contributed to this project and article equally. All authors read and approved the final manuscript.

Acknowledgment and funding

This article is the result of the support of the Research Vice-Chancellor of Mashhad University of Medical Sciences from the Ph.D. Student’s Thesis, No. 931673, which is hereby commended and appreciated.

References

  • 1. FauciABraunwaldEKasperDHauserSLongoDJamesonJHarrison’s Principles of Internal Medicine17th EditionMcgraw-hill2008
  • 2. OxfordLEMcClayJComplications of acute sinusitis in childrenOtolaryngology-Head and Neck Surgery20051331327[PubMed][Google Scholar]
  • 3. DurrDGDesrosiersMYDassaCImpact of rhinosinusitis in health care delivery: the Quebec experienceThe Journal of otolaryngology2001302937[PubMed][Google Scholar]
  • 4. BenningerMSFergusonBJHadleyJAHamilosDLJacobsMKennedyDWOtolaryngology - Head and Neck Surgery20031293 SupplementS132[PubMed]
  • 5. AndySASarookhaniDTaviranyMRPrevalence of Sinusitis in Iran: a systematic review and meta-analysis studyDer Pharmacia Lettre201685319[Google Scholar]
  • 6. SafariMMohebbiNAssessment of the prevalence of sinusitis in children under the age of 12 years with asthma in HamedanThe Iranian Journal of Otorhinolaryngology20102131338[Google Scholar]
  • 7. EhsanipourFJavaher TarashNPirdehghanAThe Prevalence of Sinusitis in Young Asthmatic Patients(2–16y) Referred to Rasoul-e-Akram Hospital During 1993–2003RJMS20051245316[Google Scholar]
  • 8. GliklichREMetsonRThe health impact of chronic sinusitis in patients seeking otolaryngologic careOtolaryngology-Head and Neck Surgery199511311049[PubMed][Google Scholar]
  • 9. GoetzelRZHawkinsKOzminkowskiRJWangSThe health and productivity cost burden of the “top 10” physical and mental health conditions affecting six large US employers in 1999Journal of occupational and environmental medicine2003451514[PubMed][Google Scholar]
  • 10. AnandVKEpidemiology and economic impact of rhinosinusitisAnnals Of Otology Rhinology And Laryngology2004113535[PubMed][Google Scholar]
  • 11. ChungSDHungSHLinHCLinCCHealth care service utilization among patients with chronic rhinosinusitis: a population-based studyThe Laryngoscope2014124612859[PubMed][Google Scholar]
  • 12. Van CrombruggenKZhangNGevaertPTomassenPBachertCPathogenesis of chronic rhinosinusitis: inflammationJ Allergy Clin Immunol2011128472832[PubMed][Google Scholar]
  • 13. FokkensWJLundVJMullolJBachertCAlobidIBaroodyFEPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologistsRhinology2012501112[PubMed][Google Scholar]
  • 14. ProbstRGreversGBasic Otorhinolaryngology: A Step-by-Step Learning GuideThieme2011
  • 15. WynnRHar-ElGRecurrence rates after endoscopic sinus surgery for massive sinus polyposisThe Laryngoscope200411458113[PubMed][Google Scholar]
  • 16. RotenbergBWBertensKAUse of complementary and alternative medical therapies for chronic rhinosinusitis: a canadian perspectiveJ Otolaryngol Head Neck Surg201039558693[PubMed][Google Scholar]
  • 17. HatipoğluURubinsteinIAnti-inflammatory treatment of chronic rhinosinusitis: a shifting paradigmCurrent allergy and asthma reports20088215461[PubMed][Google Scholar]
  • 18. HozniSAzmiyan MoghadamFYeganehMHaghshenasSEvaluation of Demographic Characteristics and Attitudes about Traditional Medicine among Patients Refered to a ClinicJournal of Guilan University of Medical Sciences20152494729[Google Scholar]
  • 19. GuoRCanterPHErnstEHerbal medicines for the treatment of rhinosinusitis: a systematic reviewOtolaryngology-Head and Neck Surgery20061354496506[PubMed][Google Scholar]
  • 20. Ghazi-MoghadamKInançlıHMBazazyNPlinkertPKEfferthTSertelSPhytomedicine in Otorhinolaryngology and Pulmonology: Clinical Trials with Herbal RemediesPharmaceuticals20125885374[PubMed][Google Scholar]
  • 21. ChitsazMMohammadiHNMKamalinejadCEAnti-bacterial effects of the plant Polk (Stachys schtschegleevii) in vitro2007Bimonthly Journal of Shahed University67[Google Scholar]
  • 22. SüleymanHDemirezerKuruüzümABanoğluZGöçerFÖzbakirGAntiinflammatory effect of the aqueous extract from Rumex patientia rootsJournal of ethnopharmacology19996521418[PubMed][Google Scholar]
  • 23. ElahiHMasroorchehrMRNematiSKamalinejadMBesharatMHajimehdipoorHHistorical Applications of Nigella sativa L.(Black cumin) in the Treatment of Zokam and Nazleh in Persian MedicineJournal of Research on History of Medicine2014311120[Google Scholar]
  • 24. AvicennaHGhanoon fe teb. Beirut: Aljoze SalesDarolhaya Altras Alarabi2004413[Google Scholar]
  • 25. Aghili KhorasaniMHGharabadin e kabir (persian)QomNoor e vahy2011954
  • 26. JalessiMFarhadiMKamravaSKAmintehranEAsghariARezaei HemamiMThe Reliability and Validity of the Persian Version of Sinonasal Outcome Test 22 (Snot 22) QuestionnairesIranian Red Crescent Medical Journal20131554048[PubMed][Google Scholar]
  • 27. MadaniSKousarianMKhalilianARabieiKAzadbakhtMOriganum Vulgar Inhaler in The Treatment of Chronic Rhinosinositis, A Double Blind Placebo Controlled Randomized Clinical TrialJournal of Mazandaran University of Medical Sciences2007[Google Scholar]
  • 28. NeherAGstottnerMThaurerMAugustijnsPReineltMSchobersbergerWInfluence of essential and fatty oils on ciliary beat frequency of human nasal epithelial cellsAmerican journal of rhinology20082221304[PubMed][Google Scholar]
  • 29. GiovanniniDGismondiABassoACanutiLBragliaRCaniniALavandula angustifolia Mill. Essential Oil Exerts Antibacterial and Anti-Inflammatory Effect in Macrophage Mediated Immune Response to Staphylococcus aureusImmunological investigations20164511128[PubMed][Google Scholar]
  • 30. OzogulYKuleyEUcarYOzogulFAntimicrobial Impacts of Essential Oils on Food Borne-PathogensRecent patents on food, nutrition & agriculture2015715361[PubMed][Google Scholar]
  • 31. PrusinowskaRSmigielskiKStobieckaAKunicka-StyczynskaAHydrolates from lavender (Lavandula angustifolia)--their chemical composition as well as aromatic, antimicrobial and antioxidant propertiesNatural product research201630438693[PubMed][Google Scholar]
  • 32. GeorgievYNOgnyanovMHKiyoharaHBatsalovaTGDzhambazovBMCizMAcidic polysaccharide complexes from purslane, silver linden and lavender stimulate Peyer’s patch immune cells through innate and adaptive mechanismsInternational journal of biological macromolecules2017105Pt 173040[PubMed][Google Scholar]
  • 33. GostnerJMGanzeraMBeckerKGeislerSSchroecksnadelSUberallFLavender oil suppresses indoleamine 2,3-dioxygenase activity in human PBMCBMC complementary and alternative medicine201414503[PubMed][Google Scholar]
  • 34. Kiecolt-GlaserJKGrahamJEMalarkeyWBPorterKLemeshowSGlaserROlfactory influences on mood and autonomic, endocrine, and immune functionPsychoneuroendocrinology200833332839[PubMed][Google Scholar]
  • 35. TrellakisSFischerCRydleuskayaATagaySBruderekKGreveJSubconscious olfactory influences of stimulant and relaxant odors on immune functionEur Arch Otorhinolaryngol20122698190916[PubMed][Google Scholar]
  • 36. de la PuertaRMartinez-DominguezERuiz-GutierrezVEffect of minor components of virgin olive oil on topical antiinflammatory assaysZeitschrift fur Naturforschung C2000559–108149[PubMed][Google Scholar]
  • 37. LiuYMcKeeverLCMalikNSAssessment of the Antimicrobial Activity of Olive Leaf Extract Against Foodborne Bacterial PathogensFrontiers in microbiology20178113[PubMed][Google Scholar]
  • 38. Aparicio-SotoMSanchez-HidalgoMRosilloMACastejonMLAlarcon-de-la-LastraCExtra virgin olive oil: a key functional food for prevention of immune-inflammatory diseasesFood Funct20167114492505[PubMed][Google Scholar]
  • 39. Martin-PelaezSCastanerOSolaRMotilvaMJCastellMPerez-CanoFJInfluence of Phenol-Enriched Olive Oils on Human Intestinal Immune FunctionNutrients201684213[PubMed][Google Scholar]
  • 40. FitoMGimenoECovasMIMiroELopez-Sabater MdelCFarreMPostprandial and short-term effects of dietary virgin olive oil on oxidant/antioxidant statusLipids200237324551[PubMed][Google Scholar]
  • 41. IncaniASerraGAtzeriAMelisMPSerreliGBandinoGExtra virgin olive oil phenolic extracts counteract the pro-oxidant effect of dietary oxidized lipids in human intestinal cellsFood Chem Toxicol20169017180[PubMed][Google Scholar]
  • 42. KatsoulierisENThe olive leaf extract oleuropein exerts protective effects against oxidant-induced cell death, concurrently displaying pro-oxidant activity in human hepatocarcinoma cellsRedox Rep2016212907[PubMed][Google Scholar]
  • 43. RahmaniAHAlbuttiASAlySMTherapeutics role of olive fruits/oil in the prevention of diseases via modulation of anti-oxidant, anti-tumour and genetic activityInternational journal of clinical and experimental medicine201474799808[PubMed][Google Scholar]
  • 44. SchillaciDNapoliEMCusimanoMGVitaleMRubertoAOriganum vulgare subsp. hirtum essential oil prevented biofilm formation and showed antibacterial activity against planktonic and sessile bacterial cellsJournal of food protection20137610174752[PubMed][Google Scholar]
  • 45. BhartiVVasudevaNSharmaSDuhanJSAntibacterial activities of Origanum vulgare alone and in combination with different antimicrobials against clinical isolates of Salmonella typhiAncient science of life20133242126[PubMed][Google Scholar]
  • 46. SaeedSTariqPAntibacterial activity of oregano (Origanum vulgare Linn.) against gram positive bacteriaPak J Pharm Sci20092244214[PubMed][Google Scholar]
  • 47. KsouriSDjebirSBentorkiAAGouriAHadefYBenakhlaAAntifungal activity of essential oils extract from Origanum floribundum Munby, Rosmarinus officinalis L. and Thymus ciliatus Desf. against Candida albicans isolated from bovine clinical mastitisJ Mycol Med20172722459[PubMed][Google Scholar]
  • 48. WallerSBHoffmannJFMadridIMPicoliTCleffMBChavesFCPolar Origanum vulgare (Lamiaceae) extracts with antifungal potential against Sporothrix brasiliensisMed Mycol2018562225233[PubMed][Google Scholar]
  • 49. BhartiVVasudevaNKumarSAnti-oxidant studies and anti-microbial effect of Origanum vulgare Linn in combination with standard antibioticsAyu2014351718[PubMed][Google Scholar]
  • 50. AshrafAAshrafMMRafiqeAAslamBGalaniSZafarSIn vivo antiviral potential of Glycyrrhiza glabra extract against Newcastle disease virusPak J Pharm Sci201730256772[PubMed][Google Scholar]
  • 51. ChakotiyaASTanwarASrivastavaPNarulaASharmaRKEffect of aquo-alchoholic extract of Glycyrrhiza glabra against Pseudomonas aeruginosa in Mice Lung Infection ModelBiomedicine & pharmacotherapy2017901718[PubMed][Google Scholar]
  • 52. SharmaHYunusGYAgrawalRKalraMVermaSBhattarSAntifungal efficacy of three medicinal plants Glycyrrhiza glabra, Ficus religiosa, and Plantago major against oral Candida albicans: A comparative analysisIndian journal of dental research20162744336[PubMed][Google Scholar]
  • 53. HejaziIIKhanamRMehdiSHBhatARMoshahid Alam RizviMIslamANew insights into the antioxidant and apoptotic potential of Glycyrrhiza glabra L. during hydrogen peroxide mediated oxidative stress: An in vitro and in silico evaluationBiomedicine & pharmacotherapy20179426579[PubMed][Google Scholar]
  • 54. FranceschelliSPesceMVinciguerraIFerroneARiccioniGPatrunoALicocalchone-C extracted from Glycyrrhiza glabra inhibits lipopolysaccharide-interferon-gamma inflammation by improving antioxidant conditions and regulating inducible nitric oxide synthase expressionMolecules2011167572034[PubMed][Google Scholar]
  • 55. LiCEomTJeongYGlycyrrhiza glabra L. Extract Inhibits LPS-Induced Inflammation in RAW MacrophagesJournal of nutritional science and vitaminology201561537581[PubMed][Google Scholar]
  • 56. BrushJMendenhallEGuggenheimAChanTConnellyESoumyanathAThe effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and immune cell activation in humansPhytotherapy research200620868795[PubMed][Google Scholar]
  • 57. AvicennaACanon of MedicineBeirutDar ehya toras al-arabi200516
  • 58. JorjaniSIzakhireh Kharazmshahi1 edQomEhya’e tibbe tabiee
  • 59. AghiliMHMakhzan-al-AdviaRahimiRShams-ArdekaniMRFarjadmandFTehran, IranTehran University of Medical Sciences2009143441481
  • 60. khanA’azamChashtiMThe Grater Exir1 edTehranResearch Institute for Islamic and Complementary Medicine2008121
  • 61. Ibne-NafisA’shshamel fes senaa’tot tebbiah1 edTehranResearch Institute for Islamic and Complementary Medicine2000267
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.